The therascreen PDGFRA kit has received approval as a companion diagnostic to AYVAKIT. Credit: Blueprint Medicines Corporation/PRNewswire.

Qiagen has received approval from the US Food and Drug Administration (FDA) for its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit) as a companion diagnostic to Blueprint Medicines’ AYVAKIT (avapritinib) in gastrointestinal stromal tumours (GIST).

The companion diagnostic will assist clinicians in identifying patients with GIST who could potentially receive treatment with AYVAKIT.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AYVAKIT received approval in the US to treat adults with unresectable or metastatic GIST that carries a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

Qiagen and Blueprint worked together to develop the PDGFRA assay, which is said to be the first to secure FDA approval as a companion diagnostic.

The real-time qualitative PCR in vitro diagnostic assay can identify the D842V somatic mutation in the PDGFRA gene for determining the patients eligible for AYVAKIT treatment.

See Also:

It utilises genomic DNA extracted from the formalin-fixed paraffin-embedded (FFPE) tumour tissue of a patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The QIAamp DSP DNA FFPE Tissue Kit is used to process FFPE tumour specimens, while the Rotor-Gene Q (RGQ) MDx instrument can help in DNA amplification and mutation detection.

Qiagen Translational Science and Precision Diagnostics head and vice-president Jonathan Arnold said: “The therascreen PDGFRA kit is an FDA-approved and validated test, delivering results in a fast turnaround time.

“This ensures that physicians receive results promptly, enabling them to make informed treatment decisions for their GIST patients in a timely and effective manner.”